神经在线 第3页
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced-爱医学

PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced

WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
eason的头像-爱医学eason1年前
540
Importance of Nonmotor Features When Diagnosing Epilepsy in Adolescents-爱医学

Importance of Nonmotor Features When Diagnosing Epilepsy in Adolescents

Jacqueline A. French, MDCredit: NYU LangoneAccording to a recently published study in Neurology, findings showed that nonmotor seizures go undetected two-thirds of the time in pedi...
eason的头像-爱医学eason1年前
530
Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim-爱医学

Improvements in Neurological Assessments and Decreased Biological Age Seen With Alzheimer Agent Bezisterim

In a randomized, placebo-controlled trial, bezisterim (BioVie), an oral, small molecule, blood-brain permeable compound in development for Alzheimer disease (AD), demonstrated pote...
eason的头像-爱医学eason1年前
520
Depression Predisposes Parkinson Disease, Associated With Worse Disease Severity-爱医学

Depression Predisposes Parkinson Disease, Associated With Worse Disease Severity

Using data from more than 430,000 participants with 14.1 years of follow-up, findings from a recently published study showed that depression is common in patients with Parkinson di...
eason的头像-爱医学eason1年前
520
NeurologyLive® Brain Games: May 12, 2024-爱医学

NeurologyLive® Brain Games: May 12, 2024

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topi...
eason的头像-爱医学eason1年前
510
Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease-爱医学

Basal Ganglia Activity Associated With REM Sleep Behavior Disorder in Parkinson Disease

Jian-Guo Zhang, MD, PhD(Credit: Capital Medical University)Newly published in the Journal of Neurology, Neurosurgery and Psychiatry, findings showed that basal ganglia activities a...
eason的头像-爱医学eason1年前
500
FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1-爱医学

FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1

Sarah Boyce(Credit: Avidity)According to a recent announcement, the FDA has granted breakthrough therapy designation to AOC 1001 (Avidity Biosciences), an investigational treatment...
eason的头像-爱医学eason1年前
500
Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680-爱医学

Alkermes Initiates Phase 2 Vibrance-1 Trial of Narcolepsy Agent ALKS 2680

Craig Hopkinson, MD(Credit: LinkedIn)According to a recent announcement, Alkermes has initiated its randomized, double-blind, dose-range-finding, placebo-controlled phase 2 Vibranc...
eason的头像-爱医学eason1年前
490
Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS-爱医学

Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

WATCH TIME: 5 minutes'This approach with the nasal administration of the drug, we believe, actually leads to a modulation of the immune system in such a way that it makes it more r...
eason的头像-爱医学eason1年前
450
This Week on NeurologyLive® — May 13 2024-爱医学

This Week on NeurologyLive® — May 13 2024

Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive®, there are a number of hot topics that we will be post...
eason的头像-爱医学eason1年前
450